Fonar has retained an investment banker to assess its MRI operations, the Melville, NY, company announced on March 3. While Fonar executives aren’t providing any details about the firm’s intentions, the company did say that it plans to make
Fonar has retained an investment banker to assess its MRI operations, the Melville, NY, company announced on March 3. While Fonar executives arent providing any details about the firms intentions, the company did say that it plans to make the investment community aware of the new MRI technologies amassed by Fonar from its recent heavy investment in R&D that are expected to enhance shareholder value.
Its unclear whether that awareness could translate into a divestiture of the MRI business. Fonar for the last several years has been attempting a comeback in MRI, but the vendor has been stymied by a lack of market interest in its new line of Quad scanners. For the companys most recent financial period, Fonar recorded only $602,000 in product sales (SCAN 3/3/99).
On the other hand, Fonar has been successful in making acquisitions to increase its healthcare services business, which has been the engine behind the firms revenue growth. The company said its retention of an investment banker will help the firm evaluate prospective acquisitions.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.